Clinical Trial

Real-life Performance Evaluation of the LiFlow X-ray Platform

Study acronym: LiFE
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
The thoraco-abdomino-pelvic (TAP) scanner is crucial for assessing and monitoring solid cancers. However, advancements in scanner technology have led to a significant increase in data volume, from 100 images per exam 20 years ago to 2,000 today. The rising number of cancer cases and treatments requiring closer monitoring further strain the workload, prolonging interpretation time and causing delays in therapeutic management and adjustments. The limited number of radiologists contributes to this saturation, increasing the risk of missing metastatic lesions, especially in the lungs, liver, bones, peritoneum, and lymph nodes. The RECIST 1.1 criteria, introduced 15 years ago for standardized follow-up, are useful but time-consuming to implement, resulting in only a small fraction of oncology CT reports using them.
Trial Details
NCT Number NCT06999538
Lead Sponsor University Hospital, Angers
Conditions Solid Cancers
Enrollment 400 participants
Start Date 2025-09-01
Primary Completion 2026-09-01 (estimated)
Study Completion 2026-09-01 (estimated)
Updated on ClinicalTrials.gov 2025-05-31